| FDTD | finite difference time domain [method] |
|---|---|
| KDB | kinase insert domain; knowledge database |
| VH | variable domain of heavy chain; variable heavy chain |
| VL | variable domain of the light chain; variable light chain |
| CR | calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio... |
| death's-head | A naked human skull as the emblem of death; the head of the conventional personification of death. "I had rather be married to a death's-head with a bone in his mouth. <zoology> " (Shak) Death's-head moth, a very large European moth (Acherontia atropos), so called from a figure resembling a human skull on the back of the thorax. Synonym: death's-head sphinx. Source: Websters Dictionary (01 Mar 1998) |
|---|---|
| death, sudden | The sudden cessation of all vital bodily functions. Legally and medically, this includes the permanent cessation of total cerebral function, spontaneous function of the respiratory system, and spontaneous function of the circulatory system. (12 Dec 1998) |
| death, sudden, cardiac | The sudden cessation of cardiac contraction, leading to death of the heart and, ultimately, of the individual, resulting from ventricular tachycardia-fibrillation or asystole. (12 Dec 1998) |
| death trance | A condition of suspended animation, marked by unconsciousness and barely perceptible respiration and heart action. (05 Mar 2000) |
| direct maternal death | Death resulting from obstetric complications of the gestation, labour, or puerperium, and from interventions, omissions, incorrect treatment, or a chain of events caused by any of the above, indirect maternal death, an obstetric death resulting from previously existing disease or from disease developing during pregnancy, labour, or the puerperium; it is not directly due to obstetric causes, but to conditions aggravated by the physiological effects of pregnancy. (05 Mar 2000) |
| infant death | Death of a liveborn infant within the first year. (05 Mar 2000) |
| early neonatal death | Death of a liveborn infant occurring less than 7 completed days (168 hours) from the time of birth, late neonatal death, death of a liveborn infant occurring after 7 completed days of age but before 28 completed days. (05 Mar 2000) |
| foetal death | <radiology> No foetal movement, no foetal heart movement, scalp oedema, Spalding's sign, hyperextended spine, thrombus within heart (12 Dec 1998) |
| foetal death rate | The number of foetal deaths divided by the sum of live births and foetal deaths occurring in the same population during the same time period. Synonym: stillbirth rate. (05 Mar 2000) |
| local death | Death of a part of the body or of a tissue by necrosis. (05 Mar 2000) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |